Free Trial
→ Now I look stupid. Real stupid... (From Porter & Company) (Ad)
NYSE:RFL

Rafael 6/13/2023 Earnings Report

Rafael logo
$1.74 +0.03 (+1.75%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$1.73 -0.01 (-0.57%)
As of 04/25/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings History

Rafael EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Date
6/13/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rafael's Q3 2025 earnings is scheduled for Thursday, June 12, 2025, with a conference call scheduled on Tuesday, June 10, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Rafael Earnings Headlines

UFC books Rafael Fiziev vs. Ignacio Bahamondes for Azerbaijan debut event
April 26 at 3:50 PM | msn.com
Marc Lopez reveals the first thing Rafael Nadal said when he hired him as his coach
April 26 at 3:50 PM | msn.com
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
April 26, 2025 | Golden Portfolio (Ad)
Crazy Rafael Devers Stat Shows Just How Bad New Red Sox DH's 2025 Season Has Been
April 26 at 10:48 AM | msn.com
Rafael Nadal Did Not Hesitate To Start Advising Alexandra Eala, Says Her Coach
April 25 at 8:45 AM | msn.com
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role
April 24 at 4:15 PM | globenewswire.com
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles